Consistently, based on the clinical characteristics of patients with gastrointestinal cancers (Supplementary Tables 1–4), we found significant differences in ACE2 expression levels between subgroups of colon cancer patients with different metastasis (M) stages (p = 0.03) and TNM stages (p = 0.021) (Supplementary Table 1). This evidence concerns the gene ACE2 and malignant colon neoplasm.